Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients
Open Access
- 7 January 2022
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (1) , 82-87
Abstract
Objective: Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, with consequent high morbidity. Increasing evidence suggests that bladder afferent hyperexcitability, through neurogenic bladder inflammation and urothelial dysfunction, plays a key role in the pathophysiology of BPS/IC. The rationale of using phosphodiesterase type 5 inhibitors (PDE5i) would be to decrease bladder afferent hyperactivity. Detrusor relaxation, improvement of microcirculation, and a decrease in adrenergic nociceptive overactivity would be other effects in bladder tissue. We aimed to evaluate the efficacy, tolerability, and safety of a daily low dose of 5mg tadalafil in refractory BPS/IC patients. Material and methods: A total of 14 refractory BPS/IC female patients, previously evaluated with a physical examination, bladder diary, bladder-pain related visual analogue score, O’Leary-Sant Scores (OSS) for symptoms and problems, and quality of life (QoL) question from International Prostate Symptom Score, were treated with 5mg of tadalafil, for 3months. Re-evaluations occurred at 4 and 12weeks. Adverse events were assessed and recorded. Results: Urinary frequency, OSS, and QoL were significantly improved at 1-month follow-up (10 6 2.5, 21.9 6 4.1, and 4 6 1.5, respectively, P < .05). Pain intensity and volume voided were significantly improved at a 3-month follow-up (3.5 6 2 and 266.7 6 60.5, P < .05). Patients referred to urinary frequency as the most important parameter improved at 4weeks, and pain at 3months. No differences between ulcerated and nonulceratedpatients were observed. Two patients dropped out due to unsatisfactory results and two due to persistent headache and/or tachycardia, but both events were resolved after discontinuing the drug. Conclusion: Daily low-dose tadalafil is an easy, well-tolerated, and effective treatment for refractory BPS/IC in women. Cite this article as: Abreu-Mendes P, Dias N, Sima˜es J, Dinis P, Cruz F, Pinto R. Daily low dose of tadalafil improves pain and frequency inbladder pain syndrome/interstitial cystitis patients. Turk J Urol. 2022; 48(1): 82-87Keywords
This publication has 27 references indexed in Scilit:
- Pain and analgesia: The dual effect of nitric oxide in the nociceptive systemNitric Oxide, 2011
- Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial CystitisEuropean Urology, 2010
- Signalling pathways involved in sildenafil‐induced relaxation of human bladder dome smooth muscleBritish Journal of Pharmacology, 2010
- Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary TractThe Journal of Sexual Medicine, 2010
- Vardenafil Modulates Bladder Contractility Through cGMP-mediated Inhibition of RhoA/Rho Kinase Signaling Pathway in Spontaneously Hypertensive RatsThe Journal of Sexual Medicine, 2009
- Relaxant Effects of Sildenafil on the Human Isolated Bladder NeckUrology, 2009
- The Role of Cystoscopy in the Diagnosis of Hunner's Ulcer DiseaseJournal of Urology, 2008
- Prevalence of Painful Bladder Symptoms and Effect on Quality of Life in Black, Hispanic and White Men and WomenJournal of Urology, 2007
- PREVALENCE AND INCIDENCE OF INTERSTITIAL CYSTITIS IN A MANAGED CARE POPULATIONJournal of Urology, 2005
- Peripheral involvement of the nitric oxide–cGMP pathway in the indomethacin-induced antinociception in ratEuropean Journal of Pharmacology, 2004